Prostate Imaging

Anatomy

The prostate is located in the pelvic cavity inferior to the urinary bladder surrounding the prostatic urethra. The gland comprises an apex resting on the urogenital diaphragm, a base attached to the bladder neck, and inferolateral surfaces resting on the levator ani facia above the urogenital diaphragm. See Image. Median Sagittal Section of Male Pelvis Anatomy.  Anatomically, it is divided into 2 lateral (right and left) and one median lobe. Histologically, it has a central zone (CZ) comprising 25% of the prostatic mass that forms the base; a peripheral zone (PZ) surrounding the central part constituting 25% of the prostatic mass; and a transition zone (TZ) that surrounds the anterolateral portion of the urethra in a horseshoe-like fashion. It is essential to know these histological zones because 70% of the adenocarcinomas arise from the peripheral zone while 20% are from the transition zone. Only 10% of adenocarcinomas arise from the central zone. Prostatitis more often occurs in the central zone. Benign prostatic hyperplasia typically expands the transitional zone creating adenoma.

Plain Films

Plain radiographs have limited prostate evaluation utility but are rarely used as a skeletal survey to assess or follow metastases. Other imaging modalities like bone scans are used for assessing bone metastases, and computed tomography (CT) of the chest, abdomen, and pelvis are used to stage prostate cancer. Magnetic resonance imaging (MRI) of the prostate is sensitive and specific for assessing prostate malignancy and local extension. CT/MRI is also used to place radiation seeds before radiotherapy.

Computed Tomography

Detailed prostate anatomy is not well defined on the CT scan, as is its pathology. It may show a hyperdense central zone with density adjusted around 40 to 60 Hounsfield Unit (HU), and the peripheral zone may appear hypodense between 10-5 HU density.

Benign Prostatic Hyperplasia

CT scan is not typically done for diagnosis, but benign prostatic hyperplasia (BPH) is identified when the prostate extends above the pubic symphysis on axial imaging. BPH can also be diagnosed on a CT scan with a volume greater than 30 mL (measured with the help of coronal reformate images).

Prostate Inflammation

In prostatitis, the gland appears diffusely hypodense with symmetric or asymmetric enlargement. Prostatic abscesses are well-defined hypoattenuating (approximately fluid density, around -19 to 13 HU) areas with peripheral rim enhancement. The progression of the disease can be monitored with a CT scan or alternative to sonography.[1]  

Prostate CA

Prostatic malignancy appears as contrast-enhancing areas, particularly in the venous phase. These areas can be focal or diffuse and are found within the peripheral zone. CT scan has a role in carcinoma imaging to assess local and distant spread.[2]

Magnetic Resonance

MRI is an excellent modality for prostate imaging due to its better contrast resolution. MRI can differentiate anatomical zones and their abnormalities. Prostate MRI is performed with a pelvic coil and is sensitive in detecting malignancy and assessing its local extension. The use of an endorectal coil provides more information and better resolution (see Image. Normal Prostate, Magnetic Resonance Image Using Endorectal Coil). With recent advances like multiparametric MRI (mp-MRI), functional MRI, and an MRI-guided biopsy, MRI is increasingly useful in detecting low-grade or low-volume prostate carcinoma. Necessary MRI sequences include T2-weighted, diffusion-weighted imaging (DWI) along with an apparent diffusion coefficient (ADC) and dynamic intravenous contrast-enhanced imaging. DWI analyzes the diffusion of water molecules at the cellular level. ADC is a qualitative measure of average water diffusion per voxel. DWI is particularly important in the diagnosis of prostate carcinoma and prostatitis, including abscesses.[3]

Normal Anatomy

The peripheral zone is homogeneously hyperintense on T2 weighted imaging (T2WI) with the hypointense capsule. The transition zone shows heterogeneity while seminal vesicles appear uniformly hyperintense on T2WI.

BPH

MRI delineates zonal anatomy, its elements, and gland volume as well as zonal volume. BPH appears as a heterogenous TZ on T2WI. Due to glandular or stromal tissue enlargement, enlarged nodules in BPH show increased or decreased signals on T2WI. Glandular enlargement appears as bright signals on T2WI, while fibromuscular and stromal elements are dark on T2WI. Estimation of stromal and glandular ratio helps to choose appropriate medical therapy.[4] Stromal enlargement may mimic transitional zone cancer due to low intensity on T2WI, diffusion restriction, and contrast enhancement, similar to prostatic carcinoma. Stromal hyperplasia can be differentiated by having a more well-defined and encapsulated appearance.[5]

On MRI, BPH can be divided into seven types. Type 0= no/little zonal enlargement. Type 2= retrourethral. Type 3= retrourethral+ bilateral TZ. Type 4= pedunculated (multiple or solitary). Type 5= pedunculated + bilateral TZ +/- retrourethral. Type 6= subtrigonal or ectopic enlargement. Type 7= other combinations. Besides diagnosing BPH, MRI plays an important role in identifying carcinoma when a patient with BPH has increased PSA and is suspicious or at high risk for developing prostate cancer.[4]

Prostate Infection

Bacterial prostatitis is acute or chronic and is more common in the peripheral zone. Acute prostatitis appears T2 hyperintense with increased contrast enhancement. Chronic prostatitis is usually hypointense on T2 and shows poor contrast enhancement. Chronic prostatitis demonstrates increased diffuse restriction due to inflammatory cell infiltrate. These findings mimic prostatic carcinoma. However, the degree of diffusion restriction is lower than carcinoma. Non-necrotic granulomatous prostatitis also appears hypointense on T2 with diffusion restriction, but contrary to chronic prostatitis, there is no enhancement on postcontrast imaging. The necrotic area of granulomatous prostatitis shows an increased signal on T2WI. In patients with extra-prostatic extension of the granulomas, it's challenging to differentiate them from carcinomas.[5][6] Prostatitis may progress into abscesses, which is hyperintense on T2, hypointense on T1, and show peripheral contrast enhancement. The abscesses show diffusion restriction and low ADC value.[7]

Prostate Malignancy

Prostate carcinoma is related to high morbidity and mortality worldwide. MRI, especially mp-MRI, is useful for cancer detection and helps to avoid unnecessary biopsy. Pre-biopsy MRI and MRI-guided biopsy is more superior to the transrectal guided ultrasound (TRUS) biopsy.[8] Pre-biopsy MRI helps avoid over-staging errors that may occur due to biopsy artifacts.[9] MRI also detects anterior, lateral, and apex tumors, which may be missed by biopsy. The malignant lesions are typically in the peripheral zone with T2WI hypointensity, focal enhancement, and low diffusivity. Ill-defined and T2 hypointense lesions in PZ are highly suspicious for carcinoma. Though malignancy is less common in the transition zone, non circumscribed, spiculated, relatively T2 hypointense lesions are suspicious. 

MRI is also used to assess metastases that are not visualized on the bone scan or CT. It's also used to evaluate pathological fractures and associated complications. PI-RADS- Prostate Imaging Reporting and Data System is a standardized classification based on mp-MRI findings updated in 2015, known as PI-RADS version 2 = PI-RADS™ v2. According to it, the presence of clinically significant carcinoma is categorized into the following:

• PI-RADS 1: Highly unlikely; normal T2WI and diffusion-weighted (DW)/ADC
• PI-RADS 2: Unlikely-circumscribed; heterogeneity on T2WI and hypointensity PZ on DW/ADC (see Image. Magnetic Resonance Image of Prostate, Imaging Reporting and Data System-2 Classification)
• PI-RADS 3: Equivocal-heterogenous lesion with obscured margin on T2WI; hyperintense on DW &andhypointense on ADC (see Image. Magnetic Resonance Image of Prostate, Imaging Reporting and Data System 3 Classification)
• PI-RADS 4: Likely; non circumscribed </= 1.5 cm lesion, moderately homogenously hypointense on T2WI; hyperintensity on DW and hypointense on ADC
• PI-RADS 5: Highly likely; similar to PI-RADS 4 but lesion > 1.5 cm or extra-prostatic extension

Ultrasonography

Ultrasound is widely available for prostate evaluation but also for performing guided prostatic biopsy. Transabdominal (TAUS) or transrectal sonography can be used to evaluate the prostate, and transrectal is preferred for biopsy. See Image. Transrectal Ultrasound Guided Biopsy of the Prostate. The prostate is examined with TAUS by a transducer placed just above the pubic symphysis with a fluid-filled urinary bladder serving as an acoustic window. The average normal measurements are 3.75 to 4.00 × 2.5 to 3.00 × 3.1 to 3.8 cm (width x height x length) with a volume of 20 to 25 cm. The prostate volume is calculated using the formula for measuring any ellipsoidal structure is 0.5236 × height (H) × width (W) × length (L).[10]  

TAUS is limited in obese patients, and in those, bladder filling is not possible to correctly evaluate prostate volume. TRUS is performed in such cases. TRUS is also necessary for suspected prostatic pathology during the clinical exam, increased prostate-specific antigen (PSA) in the blood serum, prostatic inflammation/abscess, and follow-up of prostatic cancer, as TRUS allows detailed evaluation of the prostate. 

For TRUS, an endorectal transducer having a frequency of 8 to 10 MHz is delicately inserted into the rectum. Prostate volume is measured similarly to TRAS by obtaining width, height, and length. The gland is evaluated for its shape, symmetry, echogenicity, and integrity of the prostatic capsule. Periprostatic structures, e.g., seminal vesicles, neurovascular bundles, and blood vessels, are assessed for any abnormality, especially in suspected prostate carcinoma.[11] Elastography is a vital aid performed during TRUS to evaluate the firmness of the prostate tissue. The areas of increased firmness are often identified on elastography, which does not show any abnormal echogenicity on grayscale imaging.

Benign Prostatic Hyperplasia

TAS OR TRUS assesses the prostate volume to determine the course of management, ie, prostatic volume more than 80 cm³ qualifies for open surgery-adenomectomy; otherwise, transurethral resection is the choice for management. European Association of Urology (EAU) suggests measuring prostatic volume via TRUS and residual urinary bladder post-void urine volume through TAUS. Ultrasound examination should be supplemented by visualization of the upper urinary tract to assess the degree of urinary tract dilatation.

Prostate Inflammation

Prostatitis is usually a clinical diagnosis. Sonography in prostatitis frequently demonstrates an enlarged and/or deformed gland with inhomogenous echotexture. Acute prostatitis may result in a parenchymal abscess, which appears as a hypoechoic or fluid consistency lesion within the prostate parenchyma. Ultrasound is performed not only for diagnosis but also for planning to evacuate it under ultrasound guidance. Ultrasound is useful in intraprostatic antibiotic injections in chronic prostatitis when pain is exacerbating.[12]

Prostatic Neoplasm 

Prostatic malignancy is difficult to diagnose in the USG as the tumor is often isoechoic to the surrounding normal gland. It could be hypoechoic. The ultrasound with color Doppler or power Doppler can identify angiogenesis, showing dilated and tortuous vessels, but it cannot detect small tumor foci. The diagnostic value of ultrasound is around 30% to 40%.[11] Therefore, it's mostly used as a guidance for prostatic biopsy. It is proven to improve cancer detection, especially in men who have a positive PSA and PSA ratio.[13] The ultrasound (US) is often helpful in identifying local tumor spread and thus staging cancer.

Some advances, like elastography, identify consistency differences and help in tumor diagnosis and guided biopsy. On elastography, neoplasm consistency appears firmer than the surrounding normal tissue. 3-dimensional TRUS allows computer processing of sectional images of the prostate and adds more detailed information about the morphology, surrounding structures, etc.[11] The contrast-enhanced US has a high sensitivity to differentiate neoplasm from normal prostate tissue and is more useful for US-guided biopsies.[14]

Nuclear Medicine

Nuclear medicine plays a role in the diagnosis, staging/re-staging, and therapy of prostate carcinoma. Skeletal metastases can be identified with a bone scan. Positron emission tomography (PET) is an examination that assesses malignant activity and its spread in the body. In particular, choline derivative radiotracer, 18F-fluorocholine (F-FCH), is the currently used tracer for diagnosing prostate carcinoma. PET, when combined with CT (PET/CT) and MRI (PET/MRI), adds metabolic/functional data derived from PET to CT or MRI findings.[15][16] Prostate-specific membrane antigen (PSMA) is expressed on the cell surface of carcinoma, nodal metastasis, and metastases to the bones. Ga-labeled PSMA inhibitor is a widely used PET tracer and is now becoming popular, not only for diagnosis but also for therapy.[16]

Angiography

Angiography can be utilized for prostatic artery embolization in patients with BPH and bleeding. It is an interventional technique for managing patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia. Prostatic artry embolization improves lower urinary tract symptoms.

Clinical Significance

Prostate imaging plays a vital role in identifying various pathologies, including infection, enlargement, and carcinoma. It is crucial in staging the carcinoma. PI-RADS is a standardized classification based on MRI findings, which helps in further management. US or MRI-guided procedures are also widely used for diagnosis as well as therapy.